{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.84"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"DOR defined as the time from the date of first documentation of CR or PR according to RECIST v1.1 to the date of disease progression or death due to any cause according to Investigator assessment","groups":[{"description":"260 mg once daily (QD) orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle","id":"OG000","title":"Milademetan (RAIN-32)"}],"paramType":"NUMBER","populationDescription":"This analysis is conducted in all participants within the Centrally confirmed population (CCP) who had a confirmed CR or PR.","reportingStatus":"POSTED","timeFrame":"From start date of response to first PD or study completion date; up to 23.5 months","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}